Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies
P Lampertico, D Roulot, H Wedemeyer - Journal of hepatology, 2022 - Elsevier
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, characterised by the
greatest increase in risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma …
greatest increase in risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma …
EASL Clinical Practice Guidelines on hepatitis delta virus
Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B virus to complete its
life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic …
life cycle and cause liver damage in humans. HDV is responsible for rare acute and chronic …
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
M Jachs, C Schwarz, M Panzer, T Binter… - Alimentary …, 2022 - Wiley Online Library
Summary Background and Aim Bulevirtide (BLV) blocks the uptake of the hepatitis D virus
(HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally …
(HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally …
[HTML][HTML] Treating hepatitis D with bulevirtide–Real-world experience from 114 patients
C Dietz-Fricke, F Tacke, C Zöllner, M Demir… - Jhep Reports, 2023 - Elsevier
Background & Aims Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen.
In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most …
In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most …
Interferon‐based treatment of chronic hepatitis D
L Sandmann, H Wedemeyer - Liver International, 2023 - Wiley Online Library
Abstract Treatment of hepatitis D virus (HDV) infection has been based on the administration
of interferon‐alfa for more than three decades. First studies to treat HDV‐infected patients …
of interferon‐alfa for more than three decades. First studies to treat HDV‐infected patients …
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
E Degasperi, MP Anolli, SCU Renteria… - Journal of …, 2022 - Elsevier
Background & Aims Bulevirtide (BLV) has recently been conditionally approved for the
treatment of chronic hepatitis delta (CHD) in Europe, but its effectiveness and safety in …
treatment of chronic hepatitis delta (CHD) in Europe, but its effectiveness and safety in …
Bulevirtide in the treatment of hepatitis delta: drug discovery, clinical development and place in therapy
It has been ten years since the identification of NTCP as the cell surface receptor for HBV
and HDV entry into hepatocytes. The search for molecules interfering with the binding of …
and HDV entry into hepatocytes. The search for molecules interfering with the binding of …
A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis
MP Anolli, E Degasperi, L Allweiss, A Sangiovanni… - Journal of …, 2023 - Elsevier
Bulevirtide recently received conditional approval from the EMA for the treatment of chronic
hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first …
hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first …
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA
K Deterding, C Xu, K Port, C Dietz‐Fricke… - Journal of viral …, 2023 - Wiley Online Library
Bulevirtide (BLV) is an entry inhibitor blocking entry of HBsAg into hepatocytes by interfering
with the bile acid transporter Na+‐taurocholate co‐transporting polypeptide. We here …
with the bile acid transporter Na+‐taurocholate co‐transporting polypeptide. We here …